Tetraphase Pharmaceuticals (TTPH) Stock Price, News & Analysis

Company Overview

Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: $2.18 to $2.27
• 50-Day Range: $2.20 to $2.20
• 52-Week Range: $0.56 to $8.60
• Volume: 282,689 shs
• Average Volume: 932,542 shs
• Market Capitalization: $15.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TTPH Stock Analysis - Frequently Asked Questions

How were Tetraphase Pharmaceuticals' earnings last quarter?

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) announced its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.63) by $0.32. The biopharmaceutical company had revenue of $1.76 million for the quarter, compared to analysts' expectations of $2.45 million. Tetraphase Pharmaceuticals had a negative trailing twelve-month return on equity of 210.86% and a negative net margin of 798.18%.

When did Tetraphase Pharmaceuticals' stock split?

Tetraphase Pharmaceuticals's stock reverse split on the morning of Friday, September 27th 2019.The 1-20 reverse split was announced on Thursday, September 26th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 26th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Tetraphase Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tetraphase Pharmaceuticals investors own include Alcoa (AA), Aurinia Pharmaceuticals (AUPH), GE Aerospace (GE), Bank of America (BAC), OPKO Health (OPK), Novavax (NVAX) and Bristol Myers Squibb (BMY).

Company Calendar

• Last Earnings: 5/07/2020
• Today: 7/04/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:TTPH
• CIK: 1373707
• Web: www.tphase.com
• Phone: 617-715-3600
• Fax: N/A
• Employees: 119
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($22.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$70.08 million
• Net Margins: -798.18%
• Pretax Margin: N/A
• Return on Equity: -210.86%
• Return on Assets: -121.73%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 3.66
• Quick Ratio: 3.56

Sales & Book Value

• Annual Sales: $7.38 million
• Price / Sales: 2.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.68 per share
• Price / Book: 0.33

Miscellaneous

• Outstanding Shares: 7,263,000
• Free Float: N/A
• Market Cap: $15.98 million
• Optionable: Optionable
• Beta: 2.33